Dr. Vesole on the Mechanism of Action of Belantamab Mafodotin in Multiple Myeloma

November 12, 2020
David Vesole, MD, PhD

Partner | Cancer Centers | <b>Georgetown Lombardi Comprehensive Cancer Center</b>

David H. Vesole, MD, PhD, discusses the mechanism of action of belantamab mafodotin-blmf in multiple myeloma.

David H. Vesole, MD, PhD, director of the Myeloma Program at MedStar Georgetown University Hospital, professor of medicine at Georgetown University, co-director of the Myeloma Division and director of Myeloma Research at John Theurer Cancer Center at Hackensack University Medical Center, discusses the mechanism of action of belantamab mafodotin-blmf (Blenrep) in multiple myeloma.

Belantamab mafodotin is the first BCMA-directed therapy to receive regulatory approval in the multiple myeloma, says Vesole.

Notably, the antibody-drug conjugate consists of a ​BCMA-directed antibody ​that is conjugated to a chemotherapy drug​, Vesole explains. Furthermore, the monoclonal antibody attaches to the myeloma cell ​and is endocytosed.

​Then, lysozymes break down the link between the chemotherapy drug and the antibody, which allows the chemotherapy to ​effectively kill the ​cancer cell from within​, says Vesole.

Ultimately, belantamab mafodotin offers an option for patients who have exhausted multiple other available therapies​, concludes Vesole.


x